RxDoctor Payments Data

Cynthia Garcia, APRN

Psychiatric/Mental Health · San Antonio, TXNPI 1689249666

Payments from drug & device makers

$8,994in general payments, 2019–2025

Across 437 payments — averaging $20.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Alkermes, Inc.$1K
  • AbbVie$787
  • Neurocrine Biosciences, Inc.$766
  • Otsuka America Pharmaceutical, Inc.$735
  • plus $2K from 10 others

What the payments were for

  • Food & beverage$8,75397%
  • Education$2403%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,994 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$7,438
Medicare patients
36
Services billed
110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega TrinzaPaliperidone Palmitate22$184,046
IngrezzaValbenazine Tosylate15$126,287
Lurasidone Hcl61$43,152
Invega SustennaPaliperidone Palmitate11$38,742
RexultiBrexpiprazole19$29,130
Abilify MaintenaAripiprazole13$28,328
LybalviOlanzapine/Samidorphan Malate15$24,866
VraylarCariprazine Hcl17$24,746
Varenicline Tartrate30$8,931
Aripiprazole190$8,887
Clozapine37$6,568
Duloxetine Hcl166$5,371
Hydroxyzine Hcl88$4,520
Ziprasidone Hcl44$4,470
Divalproex Sodium ErDivalproex Sodium59$3,308

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna$389$222,78733 claims
Neurocrine Biosciences, Inc.Ingrezza$766$126,28715 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$735$57,45832 claims
Alkermes, Inc.Lybalvi$1,077$24,86615 claims
AbbVieVraylar$787$24,74617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →